高尿酸血症模型 z-bo 2020-12-30 321

　　Objective: To establish a rat model of hyperuricemia, and to explore whether hyperuricemia can cause secondary cardiovascular disease.

　　Methods: Thirty-two SPF male SD rats were randomly divided into normal control group (Group C), potassium oxonate model group (Group M1), potassium oxonate combined high-sugar and high-fat diet model group (Group M2), oxygen Potassium oxazinate combined with yeast extract feed model group (Group M3), each group had 8 animals, and the model was built continuously for 3 weeks. By comparing rats' serum uric acid (UA), blood urea nitrogen (BUN), creatinine (Cr), insulin (INS), blood glucose (GLU), triglycerides (triglyceride, TG) and other indicators, supplemented by pathological examination results to study the rat model of hyperuricemia.

　　Results: The hyperuricemia model rats replicated by administering 750 mg/kg body weight of potassium oxazinate combined with yeast extract feed had a significant increase in UA level (P<0.01), long maintenance time, and 3/8 rat The characteristics of renal pathological changes, while producing hyperuricemia, are also accompanied by changes in the levels of GLU, INS and TG, and 3/8 rat heart pathological changes, suggesting the occurrence of secondary cardiovascular pathologies.

　　Conclusion: The modeling method of potassium oxazinate combined with yeast extract feed is more suitable for the establishment of a rat model of long-term hyperuricemia than potassium oxazinate alone, and it is also accompanied by the occurrence of secondary blood glucose disorders. This modelling program can be used in animal models for the study of the mutual intervention mechanism of hyperuricemia and cardiovascular disease, and further applied to the comprehensive evaluation of preclinical pharmacodynamics of therapeutic drugs for hyperuricemia.